AZD-5099 | CAS#907543-25-3 | DNA Gyrase Modulator

MedKoo Cat#: 528415 | Name: AZD-5099

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AZD-5099 is a DNA gyrase modulator potentially for the treatment of bacterial infection.

Chemical Structure

AZD-5099

CAS#907543-25-3

Theoretical Analysis

MedKoo Cat#: 528415

Name: AZD-5099

CAS#: 907543-25-3

Chemical Formula: C21H27Cl2N5O6S

Exact Mass: 547.1059

Molecular Weight: 548.44

Elemental Analysis: C, 45.99; H, 4.96; Cl, 12.93; N, 12.77; O, 17.50; S, 5.85

Price and Availability

Size	Price	Availability
1mg	USD 150.00	Ready to ship
5mg	USD 550.00	Ready to ship
10mg	USD 750.00	Ready to ship
25mg	USD 1,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

AZD-5099; AZD 5099; AZD5099

IUPAC/Chemical Name

2-((3S,4R)-4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-3-methoxypiperidin-1-yl)-4-(((S)-1-methoxypropan-2-yl)carbamoyl)thiazole-5-carboxylic acid

InChi Key

KGZHRAVDXGQUQM-WCQGTBRESA-N

InChi Code

InChI=1S/C21H27Cl2N5O6S/c1-9(8-33-3)24-19(30)16-17(20(31)32)35-21(27-16)28-6-5-11(12(7-28)34-4)26-18(29)15-14(23)13(22)10(2)25-15/h9,11-12,25H,5-8H2,1-4H3,(H,24,30)(H,26,29)(H,31,32)/t9-,11+,12-/m0/s1

SMILES Code

O=C(C1=C(C(N[C@@H](C)COC)=O)N=C(N2C[C@H](OC)[C@H](NC(C3=C(Cl)C(Cl)=C(C)N3)=O)CC2)S1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YXM220721

QC Data

View QC data: current batch, Lot#YXM220721

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

AZD5099, an antibacterial agent, is a potent and selective bacterial topoisomerase II inhibitor.

In vitro activity:

TBD

In vivo activity:

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Reference: J Med Chem. 2014 Jul 24;57(14):6060-82. https://pubmed.ncbi.nlm.nih.gov/24959892/

Preparing Stock Solutions

The following data is based on the product molecular weight 548.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Basarab GS, Hill PJ, Garner CE, Hull K, Green O, Sherer BA, Dangel PB, Manchester JI, Bist S, Hauck S, Zhou F, Uria-Nickelsen M, Illingworth R, Alm R, Rooney M, Eakin AE. Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). J Med Chem. 2014 Jul 24;57(14):6060-82. doi: 10.1021/jm500462x. Epub 2014 Jul 8. PMID: 24959892.

In vitro protocol:

TBD

In vivo protocol:

1: Bisacchi GS, Manchester JI. A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV. ACS Infect Dis. 2015 Jan 9;1(1):4-41. doi: 10.1021/id500013t. PubMed PMID: 27620144. 2: Basarab GS, Hill PJ, Garner CE, Hull K, Green O, Sherer BA, Dangel PB, Manchester JI, Bist S, Hauck S, Zhou F, Uria-Nickelsen M, Illingworth R, Alm R, Rooney M, Eakin AE. Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). J Med Chem. 2014 Jul 24;57(14):6060-82. doi: 10.1021/jm500462x. PubMed PMID: 24959892.